World Heart (WHRT) Announces IRB Approves Ventricular Assist Device BTT Study
More News related to WHRT
- World Heart Corporation Announces the Election of a New Director
- NASDAQ Stock Market Confirms WorldHeart's Compliance With NASDAQ Listing Rule 5605
- WorldHeart Participates in NIH Award for Further Development of a Miniaturized MagLev VAD
- Wedbush Initiates Coverage on World Heart Corporation (WHRT) a Neutral
- World Heart Corp. Completes $7.3 Million Private Placement
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
World Heart Corporation (NASDAQ: WHRT) announced today that the Levacor Ventricular Assist Device (VAD) Bridge-to-Transplant (BTT) Study has been approved by the Institutional Review Board (IRB) at INTEGRIS Baptist Medical Center in Oklahoma City.
As previously announced, WorldHeart has conditional approval from the FDA for the Levacor BTT Study for ten initial study sites. Mr. J. Alex Martin, WorldHeart President and CEO said that "we are eager to move forward into the clinical setting and are extremely pleased to announce INTEGRIS Baptist's qualification status. We also continue to work closely with other participating hospitals as their IRBs review the Study protocol."
Related Categories
Corporate NewsStocks Mentioned
-0.34Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
